HOME > PUBLICATIONS > Clinical Research
| File | |
|---|---|
| Date | 2013-07-01 |
| Journal | Kim JW, Kim JH, Im SA, Kim YJ, Han HS, Kim JS, Lee KH, Kim TY, Han SW, Jeon YK, Oh DY, Kim TY, Park IA., HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer. Cancer Chemother Pharmacol. 2013 Jul;72(1):109-15. |
| Visits | 512 |
